Chimerix Company Profile (NASDAQ:CMRX)

About Chimerix (NASDAQ:CMRX)

Chimerix logoChimerix, Inc. is a biotechnology company. The Company is focused on discovering, developing and commercializing medicines that address unmet medical needs. Its lead compound, brincidofovir, is in development as an oral and intravenous (IV) formulation for the prevention and treatment of deoxyribonucleic acid (DNA) viruses, including smallpox, adenoviruses (AdV), and the human herpesviruses. It is also advancing the development of CMX521 for the treatment and prevention of norovirus. In addition, the Company has an active discovery program focusing on viral targets for which limited or no therapies are available. Brincidofovir is an investigational oral nucleotide analog that has shown spectrum antiviral activity against all five families of double-stranded deoxyribonucleic acid (dsDNA) viruses that affect humans. Oral and IV formulations of brincidofovir are in development, both of which deliver the active antiviral directly to the site of viral replication.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:CMRX
  • CUSIP: N/A
  • Web: www.chimerix.com
Capitalization:
  • Market Cap: $219.49 million
  • Outstanding Shares: 46,651,000
Average Prices:
  • 50 Day Moving Avg: $5.53
  • 200 Day Moving Avg: $5.33
  • 52 Week Range: $3.50 - $6.64
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.66
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $5.55 million
  • Price / Sales: 39.55
  • Book Value: $5.65 per share
  • Price / Book: 0.83
Profitability:
  • EBIDTA: ($68,500,000.00)
  • Net Margins: -1,451.99%
  • Return on Equity: -32.09%
  • Return on Assets: -30.80%
Debt:
  • Current Ratio: 26.47%
  • Quick Ratio: 26.47%
Misc:
  • Average Volume: 378,511 shs.
  • Beta: 1.62
  • Short Ratio: 5.77
 

Frequently Asked Questions for Chimerix (NASDAQ:CMRX)

What is Chimerix's stock symbol?

Chimerix trades on the NASDAQ under the ticker symbol "CMRX."

How were Chimerix's earnings last quarter?

Chimerix Inc (NASDAQ:CMRX) announced its quarterly earnings data on Tuesday, May, 9th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by $0.01. The business earned $1.08 million during the quarter, compared to analysts' expectations of $1.56 million. Chimerix had a negative return on equity of 32.09% and a negative net margin of 1,451.99%. View Chimerix's Earnings History.

Where is Chimerix's stock going? Where will Chimerix's stock price be in 2017?

4 analysts have issued 12-month target prices for Chimerix's stock. Their predictions range from $6.00 to $12.00. On average, they expect Chimerix's stock price to reach $8.00 in the next year. View Analyst Ratings for Chimerix.

What are analysts saying about Chimerix stock?

Here are some recent quotes from research analysts about Chimerix stock:

  • 1. FBR & Co analysts commented, "We attended Chimerix’s Investor/Analyst Day on April 27 in New York and came away looking forward to further clinical development in 2017 and 2018. Chimerix reported data from the single ascending dose (SAD) study with IV brincidofovir (BCV) and provided additional details on future clinical trials." (5/1/2017)
  • 2. Cowen and Company analysts commented, "CMRX is developing brincidofovir as an inhibitor of several DNA viruses." (4/28/2017)
  • 3. According to Zacks Investment Research, "Chimerix, Inc. engages in the discovery, development and commercialization of oral antiviral therapeutics for various medical needs. The Company is developing various product candidates for the treatment of dsDNA viruses, HIV, hepatitis C, influenza and smallpox which are under different phases of clinical development. It is also screening our proprietary Chimerix Chemical Library for compounds with activity against dengue virus, malaria and tuberculosis. Chimerix, Inc. is headquartered in Durham, North Carolina. " (2/16/2017)

Who are some of Chimerix's key competitors?

Who owns Chimerix stock?

Chimerix's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include FMR LLC (14.99%), Redmile Group LLC (9.27%), Vanguard Group Inc. (3.97%), Dimensional Fund Advisors LP (2.24%), Morgan Stanley (1.33%) and JPMorgan Chase & Co. (1.03%). Company insiders that own Chimerix stock include Ernest Mario, John M Leonard, M Michelle Berrey, Martha J Demski and Timothy W Trost. View Institutional Ownership Trends for Chimerix.

Who sold Chimerix stock? Who is selling Chimerix stock?

Chimerix's stock was sold by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, First Quadrant L P CA, Bogle Investment Management L P DE, Wells Fargo & Company MN, JPMorgan Chase & Co., Sabby Management LLC, Prudential Financial Inc. and KCG Holdings Inc.. Company insiders that have sold Chimerix stock in the last year include Ernest Mario and John M Leonard. View Insider Buying and Selling for Chimerix.

Who bought Chimerix stock? Who is buying Chimerix stock?

Chimerix's stock was bought by a variety of institutional investors in the last quarter, including Redmile Group LLC, Dimensional Fund Advisors LP, Morgan Stanley, Renaissance Technologies LLC, Vanguard Group Inc., Victory Capital Management Inc., TFS Capital LLC and Sessa Capital IM L.P.. Company insiders that have bought Chimerix stock in the last two years include Ernest Mario, John M Leonard, M Michelle Berrey and Martha J Demski. View Insider Buying and Selling for Chimerix.

How do I buy Chimerix stock?

Shares of Chimerix can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Chimerix stock cost?

One share of Chimerix stock can currently be purchased for approximately $4.71.

Analyst Ratings

Consensus Ratings for Chimerix (NASDAQ:CMRX) (?)
Ratings Breakdown: 3 Hold Ratings, 1 Buy Rating
Consensus Rating:Hold (Score: 2.25)
Consensus Price Target: $8.00 (70.03% upside)

Analysts' Ratings History for Chimerix (NASDAQ:CMRX)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/1/2017FBR & CoReiterated RatingHold$7.00HighView Rating Details
4/28/2017Cowen and CompanyReiterated RatingHold$6.00LowView Rating Details
8/18/2016Piper Jaffray CompaniesSet Price TargetBuy$12.00N/AView Rating Details
8/9/2016JPMorgan Chase & Co.Reiterated RatingHold$7.00N/AView Rating Details
3/1/2016Citigroup IncReiterated RatingHoldN/AView Rating Details
2/23/2016William BlairLower Price TargetMarket Perform$12.00 -> $8.00N/AView Rating Details
2/23/2016Barclays PLCDowngradeOverweight -> Equal Weight$12.00 -> $6.00N/AView Rating Details
2/22/2016Morgan StanleyDowngradeEqual Weight -> Underweight$8.00 -> $5.00N/AView Rating Details
1/3/2016Brean CapitalDowngradeHoldN/AView Rating Details
1/3/2016Stifel NicolausDowngradeHoldN/AView Rating Details
12/30/2015EmpireReiterated RatingEqual WeightN/AView Rating Details
12/30/2015Janney Montgomery ScottLower Price TargetNeutral$14.00N/AView Rating Details
9/8/2015Cantor FitzgeraldReiterated RatingBuy$57.00N/AView Rating Details
(Data available from 5/23/2015 forward)

Earnings

Earnings History for Chimerix (NASDAQ:CMRX)
Earnings by Quarter for Chimerix (NASDAQ:CMRX)
Earnings History by Quarter for Chimerix (NASDAQ:CMRX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2017Q1 2017($0.37)($0.38)$1.56 million$1.08 millionViewListenView Earnings Details
3/2/2017Q4 2016($0.37)($0.32)$0.89 million$1.98 millionViewListenView Earnings Details
11/7/2016Q3($0.39)($0.37)$1.73 million$0.65 millionViewListenView Earnings Details
8/8/2016Q2($0.51)($0.39)$1.98 million$1.80 millionViewN/AView Earnings Details
5/9/2016Q1($0.66)($0.57)$2.79 million$1.20 millionViewN/AView Earnings Details
2/29/2016Q415($0.14)($0.82)$8.07 million$3.10 millionViewListenView Earnings Details
11/5/2015Q315($0.59)($0.70)$5.01 million$2.27 millionViewListenView Earnings Details
8/6/2015Q215($0.58)($0.59)$1.37 million$4.10 millionViewListenView Earnings Details
5/11/2015Q115($0.59)($0.54)$1.19 million$1.20 millionViewListenView Earnings Details
3/6/2015Q414($0.51)($0.52)$1.13 million$1.16 millionViewListenView Earnings Details
11/7/2014Q314($0.41)($0.47)$0.40 million$1.19 millionViewN/AView Earnings Details
8/7/2014Q214($0.46)($0.39)$0.84 million$0.92 millionViewN/AView Earnings Details
5/9/2014Q1 14($0.36)($0.39)$0.85 million$0.78 millionViewN/AView Earnings Details
3/7/2014Q413($0.41)($0.31)$1.19 million$0.88 millionViewN/AView Earnings Details
11/14/2013Q3($0.38)($0.26)ViewListenView Earnings Details
8/14/2013Q2 2013($0.40)($0.91)$1.91 million$0.81 millionViewN/AView Earnings Details
5/13/2013Q1 2013($2.43)($22.58)$1.00 million$1.80 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Chimerix (NASDAQ:CMRX)
2017 EPS Consensus Estimate: ($1.86)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.42)($0.34)($0.38)
Q2 20172($0.45)($0.41)($0.43)
Q3 20172($0.54)($0.44)($0.49)
Q4 20172($0.62)($0.49)($0.56)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Chimerix (NASDAQ:CMRX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Chimerix (NASDAQ:CMRX)
Insider Ownership Percentage: 10.50%
Institutional Ownership Percentage: 68.66%
Insider Trades by Quarter for Chimerix (NASDAQ:CMRX)
Institutional Ownership by Quarter for Chimerix (NASDAQ:CMRX)
Insider Trades by Quarter for Chimerix (NASDAQ:CMRX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/28/2016Ernest MarioDirectorSell100,000$4.64$464,000.00View SEC Filing  
9/15/2016John M LeonardDirectorSell5,000$5.03$25,150.00View SEC Filing  
8/29/2016M Michelle BerreyInsiderBuy22,417$4.47$100,203.99View SEC Filing  
6/24/2016Ernest MarioDirectorBuy50,000$3.70$185,000.00View SEC Filing  
6/24/2016M Michelle BerreyCEOBuy13,188$3.69$48,663.72View SEC Filing  
5/13/2016Ernest MarioDirectorBuy10,000$4.53$45,300.00View SEC Filing  
5/11/2016Ernest MarioDirectorBuy25,000$4.85$121,250.00View SEC Filing  
5/10/2016Ernest MarioDirectorBuy800$4.76$3,808.00View SEC Filing  
3/16/2016Ernest MarioDirectorBuy25,000$5.06$126,500.00View SEC Filing  
3/15/2016Ernest MarioDirectorBuy20,000$5.13$102,600.00View SEC Filing  
3/1/2016Martha J DemskiDirectorBuy10,000$4.89$48,900.00View SEC Filing  
12/29/2015Ernest MarioDirectorBuy125,000$7.09$886,250.00View SEC Filing  
11/2/2015Martha J. DemskiDirectorSell1,126$41.35$46,560.10View SEC Filing  
10/1/2015Martha J. DemskiDirectorSell2,000$37.68$75,360.00View SEC Filing  
9/1/2015Martha J. DemskiDirectorSell2,000$48.18$96,360.00View SEC Filing  
8/21/2015John M LeonardDirectorBuy1,000$47.38$47,380.00View SEC Filing  
7/17/2015Timothy W TrostCFOSell28,000$50.00$1,400,000.00View SEC Filing  
7/1/2015Martha J DemskiDirectorSell2,000$46.03$92,060.00View SEC Filing  
6/1/2015Martha J DemskiDirectorSell2,000$41.58$83,160.00View SEC Filing  
5/1/2015Martha J DemskiDirectorSell2,000$34.71$69,420.00View SEC Filing  
3/2/2015Martha J DemskiDirectorSell2,000$40.18$80,360.00View SEC Filing  
2/2/2015Martha J DemskiDirectorSell2,000$38.38$76,760.00View SEC Filing  
1/2/2015Martha J DemskiDirectorSell2,000$41.08$82,160.00View SEC Filing  
11/5/2014John M LeonardDirectorBuy4,000$29.00$116,000.00View SEC Filing  
9/25/2014Timothy W TrostCFOSell5,000$27.75$138,750.00View SEC Filing  
9/11/2014James NiedelDirectorSell1,099,949$29.39$32,327,501.11View SEC Filing  
9/9/2014Sanderling Venture Partners V,Major ShareholderSell122,950$29.28$3,599,976.00View SEC Filing  
9/8/2014Timothy WollaegerDirectorSell100,000$24.54$2,454,000.00View SEC Filing  
9/5/2014Ernest MarioDirectorBuy10,000$23.19$231,900.00View SEC Filing  
8/25/2014Timothy W TrostCFOSell5,000$25.13$125,650.00View SEC Filing  
7/25/2014Timothy W TrostInsiderSell5,000$22.35$111,750.00View SEC Filing  
6/25/2014Timothy W TrostCFOSell5,000$22.74$113,700.00View SEC Filing  
5/27/2014Ernest MarioDirectorBuy10,000$14.22$142,200.00View SEC Filing  
5/27/2014M Michelle BerreyInsiderBuy14,065$14.22$200,004.30View SEC Filing  
5/27/2014Timothy W TrostCFOSell5,000$17.41$87,050.00View SEC Filing  
4/25/2014Timothy W TrostInsiderSell5,000$18.67$93,350.00View SEC Filing  
3/25/2014Timothy W TrostCFOSell5,000$25.37$126,850.00View SEC Filing  
2/25/2014Timothy W TrostCFOSell5,000$19.29$96,450.00View SEC Filing  
1/27/2014Timothy W TrostCFOSell5,000$18.26$91,300.00View SEC Filing  
12/26/2013Timothy W TrostCFOSell5,000$15.21$76,050.00View SEC Filing  
12/13/2013Ernest MarioDirectorBuy5,000$13.90$69,500.00View SEC Filing  
12/9/2013Rodman L DrakeDirectorBuy1,000$14.35$14,350.00View SEC Filing  
11/25/2013Ernest MarioDirectorBuy8,000$15.20$121,600.00View SEC Filing  
11/19/2013Ernest MarioDirectorBuy7,500$15.25$114,375.00View SEC Filing  
11/15/2013Rodman L DrakeDirectorBuy1,000$15.56$15,560.00View SEC Filing  
10/25/2013Timothy W TrostCFOSell5,000$16.04$80,200.00View SEC Filing  
10/23/2013Leaf Ventures Ii L.P. NewMajor ShareholderSell585,602$15.51$9,082,687.02View SEC Filing  
10/23/2013Vii L P CanaanDirectorSell674,771$15.51$10,465,698.21View SEC Filing  
8/30/2013Ernest MarioDirectorBuy5,064$15.82$80,112.48View SEC Filing  
8/26/2013Ernest MarioDirectorBuy5,960$17.20$102,512.00View SEC Filing  
8/23/2013M Michelle BerreyInsiderBuy5,540$18.70$103,598.00View SEC Filing  
8/20/2013Ernest MarioDirectorBuy4,040$17.48$70,619.20View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Chimerix (NASDAQ:CMRX)
Latest Headlines for Chimerix (NASDAQ:CMRX)
Source:
DateHeadline
seekingalpha.com logoChimerix: This Misunderstood Biotech, Trading Near Cash, Offers Substantial Upside - Seeking Alpha
seekingalpha.com - May 18 at 4:17 PM
americanbankingnews.com logoChimerix Inc (CMRX) to Post Q2 2017 Earnings of ($0.45) Per Share, William Blair Forecasts
www.americanbankingnews.com - May 12 at 10:40 AM
americanbankingnews.com logoQ2 2017 Earnings Estimate for Chimerix Inc Issued By FBR & Co (CMRX)
www.americanbankingnews.com - May 11 at 9:09 AM
americanbankingnews.com logoChimerix Inc (CMRX) Issues Quarterly Earnings Results
www.americanbankingnews.com - May 10 at 4:56 PM
finance.yahoo.com logoChimerix outlines plans for DNA virus drug
finance.yahoo.com - May 10 at 8:17 AM
finance.yahoo.com logoInvestor Network: Chimerix, Inc. to Host Earnings Call
finance.yahoo.com - May 9 at 4:23 PM
finance.yahoo.com logoChimerix Announces First Quarter 2017 Financial Results
finance.yahoo.com - May 9 at 8:12 AM
americanbankingnews.com logoPositive Media Coverage Very Likely to Impact Chimerix (CMRX) Share Price
www.americanbankingnews.com - May 3 at 8:54 PM
americanbankingnews.com logo Brokerages Anticipate Chimerix Inc (CMRX) Will Post Quarterly Sales of $1.56 Million
www.americanbankingnews.com - May 3 at 2:35 PM
finance.yahoo.com logoChimerix to Announce First Quarter 2017 Financial Results on May 9, 2017
finance.yahoo.com - May 2 at 5:29 PM
americanbankingnews.com logoChimerix Inc (CMRX) Receives Hold Rating from FBR & Co
www.americanbankingnews.com - May 1 at 7:36 PM
americanbankingnews.com logoZacks: Brokerages Expect Chimerix Inc (CMRX) to Announce -$0.37 Earnings Per Share
www.americanbankingnews.com - May 1 at 5:46 PM
americanbankingnews.com logoSomewhat Negative Media Coverage Likely to Impact Chimerix (CMRX) Stock Price
www.americanbankingnews.com - April 30 at 11:39 AM
americanbankingnews.com logoChimerix Inc (CMRX) Stock Rating Reaffirmed by Cowen and Company
www.americanbankingnews.com - April 29 at 1:02 AM
americanbankingnews.com logoChimerix (CMRX) Receives Media Sentiment Rating of 0.56
www.americanbankingnews.com - April 26 at 11:34 AM
finance.yahoo.com logoETFs with exposure to Chimerix, Inc. : April 24, 2017
finance.yahoo.com - April 24 at 4:18 PM
americanbankingnews.com logoFavorable News Coverage Somewhat Likely to Affect Chimerix (CMRX) Share Price
www.americanbankingnews.com - April 21 at 5:09 PM
finance.yahoo.com logoChimerix to Host Annual Investor Update on April 27, 2017
finance.yahoo.com - April 20 at 4:31 PM
finance.yahoo.com logoMedical Device Stocks to Beat Estimates this Earnings Season
finance.yahoo.com - April 18 at 4:13 PM
americanbankingnews.com logoChimerix (CMRX) Earns Media Impact Rating of -0.08
www.americanbankingnews.com - April 16 at 11:51 AM
americanbankingnews.com logoZacks: Brokerages Expect Chimerix Inc (CMRX) Will Announce Earnings of -$0.37 Per Share
www.americanbankingnews.com - April 10 at 11:27 AM
finance.yahoo.com logoETFs with exposure to Chimerix, Inc. : April 7, 2017
finance.yahoo.com - April 7 at 4:22 PM
finance.yahoo.com logoCHIMERIX INC Financials
finance.yahoo.com - March 8 at 5:07 PM
finance.yahoo.com logoEdited Transcript of CMRX earnings conference call or presentation 2-Mar-17 1:30pm GMT
finance.yahoo.com - March 2 at 9:38 PM
sg.finance.yahoo.com logoChimerix reports 4Q loss
us.rd.yahoo.com - March 2 at 4:38 PM
biz.yahoo.com logoCHIMERIX INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
biz.yahoo.com - March 2 at 4:38 PM
finance.yahoo.com logoChimerix Announces Fourth Quarter and Full Year 2016 Financial Results
finance.yahoo.com - March 2 at 7:23 AM
biz.yahoo.com logoQ4 2016 Chimerix Inc Earnings Release - Before Market Open
biz.yahoo.com - March 2 at 7:23 AM
finance.yahoo.com logoChimerix to Present at Cowen and Company 37th Annual Health Care Conference
finance.yahoo.com - February 28 at 1:03 PM
finance.yahoo.com logoChimerix to Announce Fourth Quarter and Full Year 2016 Financial Results on March 2, 2017
finance.yahoo.com - February 23 at 4:21 PM
finance.yahoo.com logoChimerix Announces Final Data from AdVise Trial of Brincidofovir at BMT Tandem Meetings
finance.yahoo.com - February 22 at 11:17 AM
finance.yahoo.com logo8:06 am Chimerix announces the presentation of final data from the AdVise trial of brincidofovir for the treatment of adenovirus infection in allogeneic hematopoietic cell transplant recipients at the BMT Tandem Meetings; results show highe
finance.yahoo.com - February 22 at 11:17 AM
finance.yahoo.com logoWill Chimerix (CMRX) Continue to Surge Higher?
finance.yahoo.com - January 24 at 4:58 PM
biz.yahoo.com logoCHIMERIX INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
biz.yahoo.com - January 6 at 4:49 PM
streetinsider.com logoChimerix (CMRX) Names Randall Lanier as CSO; Roy Ware CMTO
www.streetinsider.com - January 5 at 9:56 PM
us.rd.yahoo.com logo4:30 pm Chimerix appoints Randall Lanier, PhD, as Chief Science Officer
us.rd.yahoo.com - January 5 at 9:55 PM
finance.yahoo.com logoChimerix Appoints Randall Lanier, PhD as Chief Science Officer, and Roy W. Ware, PhD, MBA as Chief Manufacturing and Technology Officer
finance.yahoo.com - January 5 at 4:54 PM
finance.yahoo.com logoChimerix to Present at the 35th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 4 at 5:24 PM

Social

Chimerix (CMRX) Chart for Tuesday, May, 23, 2017

This page was last updated on 5/23/2017 by MarketBeat.com Staff